Is The Joint Corp (JYNT) overvalued? · P/E 92, rev $30.2M
The Joint Corp (JYNT) is a medical care facilities company listed on US.
This page asks whether The Joint Corp (JYNT) looks expensive on cached numbers — not a short thesis.
Latest reported JYNT revenue for 2024-09-30 was $30.2M. Net income was -$3.2M. Revenue was down 0.2% from 2024-06-30 to 2024-09-30. JYNT currently screens at market cap $117.9M and trailing P/E 91.9.
JYNT currently screens at market cap $117.9M and trailing P/E 91.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next JYNT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the JYNT stock page for the full model, not this heading.
Not investment advice.